5J9L
Crystal structure of CPT1691 bound to TAK1-TAB1
Summary for 5J9L
| Entry DOI | 10.2210/pdb5j9l/pdb |
| Descriptor | Mitogen-activated protein kinase kinase kinase 7,TGF-beta-activated kinase 1 and MAP3K7-binding protein 1, N-(4-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide (3 entities in total) |
| Functional Keywords | mitogen-activated protein kinase kinase kinase 7/tgf-beta-activated kinase 1 and map3k7-binding protein 1, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
| Biological source | Homo sapiens (Human) More |
| Total number of polymer chains | 1 |
| Total formula weight | 35250.64 |
| Authors | Gurbani, D.,Westover, K.D. (deposition date: 2016-04-10, release date: 2017-02-15, Last modification date: 2023-09-27) |
| Primary citation | Tan, L.,Gurbani, D.,Weisberg, E.L.,Hunter, J.C.,Li, L.,Jones, D.S.,Ficarro, S.B.,Mowafy, S.,Tam, C.P.,Rao, S.,Du, G.,Griffin, J.D.,Sorger, P.K.,Marto, J.A.,Westover, K.D.,Gray, N.S. Structure-guided development of covalent TAK1 inhibitors. Bioorg. Med. Chem., 25:838-846, 2017 Cited by PubMed Abstract: TAK1 (transforming growth factor-β-activated kinase 1) is an essential intracellular mediator of cytokine and growth factor signaling and a potential therapeutic target for the treatment of immune diseases and cancer. Herein we report development of a series of 2,4-disubstituted pyrimidine covalent TAK1 inhibitors that target Cys174, a residue immediately adjacent to the 'DFG-motif' of the kinase activation loop. Co-crystal structures of TAK1 with candidate compounds enabled iterative rounds of structure-based design and biological testing to arrive at optimized compounds. Lead compounds such as 2 and 10 showed greater than 10-fold biochemical selectivity for TAK1 over the closely related kinases MEK1 and ERK1 which possess an equivalently positioned cysteine residue. These compounds are smaller, more easily synthesized, and exhibit a different spectrum of kinase selectivity relative to previously reported macrocyclic natural product TAK1 inhibitors such as 5Z-7-oxozeanol. PubMed: 28011204DOI: 10.1016/j.bmc.2016.11.035 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.7515 Å) |
Structure validation
Download full validation report






